Thiazolidinedione therapy for nonalcoholic steatohepatitis: Go, stop, or proceed with caution?

Hepatology

Volumn 51, Issue 2, 2010, Pages 366-369

  Harrison, Stephen A ^a  

^a BROOKE ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; FATTY ACID; GLITAZONE DERIVATIVE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PEGINTERFERON; PIOGLITAZONE; PLACEBO; RIBAVIRIN; ROSIGLITAZONE; TRIACYLGLYCEROL;

BARIATRIC SURGERY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG MECHANISM; EDITORIAL; GLUCONEOGENESIS; HEPATITIS C; HISTOPATHOLOGY; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; LIPOGENESIS; LIVER BIOPSY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

FATTY LIVER; HUMANS; HYPOGLYCEMIC AGENTS; THIAZOLIDINEDIONES;

EID: 75449103119     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.23473     Document Type: Editorial

References (24)

1. Pillai AA, Rinella ME. Nonalcoholic fatty liver disease: is bariatric surgery the answer? Clin Liv Dis 2009;13:689-710.
2. Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis; a randomized, prospective trial. HEPATOLOGY 2009;49:80-86.
3. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-1118.
4. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006;116:1784-1792.
5. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297-2307.
6. Marra F, Bertolani C. Adipokines in liver disease. HEPATOLOGY 2009;50:957-969.
7. Adachi M, Brenner DA. High molecular weight adiponectin inhibits proliferation of hepatic stellate cells via activation of adenosine monophosphate-activated protein kinase. HEPATOLOGY 2008;47:677-685.
8. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005;28:1547-1554.
9. Beysen C, Murphy EJ, Nagaraja H, Decaris M, Riiff T, Fong A, et al. A pilot study of the effects of pioglitazone and rosiglitazone on de novo lipogenesis in type 2 diabetes. J Lipid Res 2008;49:2657-2663.
10. Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D'Agostino RB Sr, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006;296:2572-2581.
11. Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008;299:1561-1573.
12. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone. HEPATOLOGY 2003;38:1008-1017.
13. Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L, et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial. Gastroenterology 2008;135:100-110.
14. Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove A, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008;135:1176-1184.
15. Sanyal AJ. A randomized controlled trial of pioglitazone or vitamin E for nonalcoholic steatohepatitis (PIVENS) [Abstract]. HEPATOLOGY 2009;50(Suppl.):LB4.
16. Argo CK, Northrup PG, Al-Osaimi AMS, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 2009;51:371-379.
17. Ratziu V, Charlotte F, Bernhardt C, Giral P, Halbron M, Le Naour G. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT-2) extension trial. HEPATOLOGY 2010;51:445-453.
18. The DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. The Lancet 2006;368:1096-1105.
19. Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, et al. Effect of pioglitazone on pancreatic β-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 2006;55:517-522.
20. Lincoff A, Wolski K, Nicholls S, Nissen S. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus. A meta-analysis of randomized trials. JAMA 2007;298:1180-1188.
21. Adams LA, Waters OR, Knuiman MW, Elliott RR, Olynyk JK. NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am J Gastroenterol 2009;104:861-867.
22. Arslan U, Turkoglu S, Balcioglu S, Tavil Y, Karakan T, Cengel A. Association between nonalcoholic fatty liver disease and coronary artery disease. Coron Artery Dis 2007;18:433-436.
23. Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, Gramlich T, et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009;7:234-238.
24. Mathurin P, Hollebecque A, Arnalsteen L, Buob D, Leteurtre E, Caiazzo R, et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 2009;137:532-540.